Physician profile
Paul E Sax
NPI 1306809892
$319,544.28
in general payments reported to CMS, 2019-2025
9 companies · $28K in 2025
The $28K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $40K · 2021: $41K · 2022: $37K · 2023: $51K · 2024: $28K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $90K · Travel and Lodging: $13K · Food and Beverage: $3,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $90,317.98 |
| Travel and Lodging | $13,349.66 |
| Food and Beverage | $3,235.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $143,057.71 | 2019-2025 | Sunlenca |
| Viiv Healthcare Company | $108,845.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $40,940.51 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $11,343.42 | 2020-2023 | Symtuza |
| Glaxosmithkline, LLC. | $6,703.55 | 2022 | |
| Shionogi INC | $5,670.00 | 2025 | S-217622, Fetroja |
| Abbvie INC. | $2,025.00 | 2024 | |
| Janssen Products, LP | $860.00 | 2022 | |
| Insmed, INC. | $99.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.